Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremie Calais

Showing results (101-110 of 207) with videos related to

Pageof 21
Sort By:
Current Treatment Options in Oncology|January 25, 2024
Impact of PSMA PET on Prostate Cancer ManagementAdam B Weiner, Raag Agrawal, Luca F Valle, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 1, 2024
Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate CancerJohn Nikitas, Angela Castellanos Rieger, Andrea Farolfi, et al.
BMC Cancer|May 8, 2021
Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocolJeremie Calais, Shaojun Zhu, Nader Hirmas, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 30, 2024
FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot StudyRong Rong Huang, Chunlai Zuo, Christine E Mona, et al.
Clinical Genitourinary Cancer|October 9, 2018
Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by <sup>68</sup>Ga-PSMA-11 PET/CTGiulia Polverari, Francesco Ceci, Martin Allen-Auerbach, et al.
EJNMMI Research|October 16, 2020
[<sup>18</sup>F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trialGiulia Polverari, Francesco Ceci, Roberto Passera, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 12, 2020
Impact of <sup>68</sup>Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center StudyIda Sonni, Matthias Eiber, Wolfgang P Fendler, et al.
European Urology Oncology|September 22, 2020
Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center StudyAndrew T Lenis, Aydin Pooli, Patrick M Lec, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 29, 2022
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteriaAndrei Gafita, Isabel Rauscher, Wolfgang P Fendler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 21, 2019
Can the Injected Dose Be Reduced in <sup>68</sup>Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection?Isabel Rauscher, Wolfgang P Fendler, Thomas A Hope, et al.
Pageof 21

Showing results (101-110 of 207) with videos related to

Sort By:
Pageof 21
Current Treatment Options in Oncology|January 25, 2024
Impact of PSMA PET on Prostate Cancer ManagementAdam B Weiner, Raag Agrawal, Luca F Valle, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 1, 2024
Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate CancerJohn Nikitas, Angela Castellanos Rieger, Andrea Farolfi, et al.
BMC Cancer|May 8, 2021
Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocolJeremie Calais, Shaojun Zhu, Nader Hirmas, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 30, 2024
FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot StudyRong Rong Huang, Chunlai Zuo, Christine E Mona, et al.
Clinical Genitourinary Cancer|October 9, 2018
Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by <sup>68</sup>Ga-PSMA-11 PET/CTGiulia Polverari, Francesco Ceci, Martin Allen-Auerbach, et al.
EJNMMI Research|October 16, 2020
[<sup>18</sup>F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trialGiulia Polverari, Francesco Ceci, Roberto Passera, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 12, 2020
Impact of <sup>68</sup>Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center StudyIda Sonni, Matthias Eiber, Wolfgang P Fendler, et al.
European Urology Oncology|September 22, 2020
Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center StudyAndrew T Lenis, Aydin Pooli, Patrick M Lec, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 29, 2022
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteriaAndrei Gafita, Isabel Rauscher, Wolfgang P Fendler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 21, 2019
Can the Injected Dose Be Reduced in <sup>68</sup>Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection?Isabel Rauscher, Wolfgang P Fendler, Thomas A Hope, et al.
Pageof 21